| 前收盘价格 | 1.53 |
| 收盘价格 | 1.21 |
| 成交量 | 6,566,256 |
| 平均成交量 (3个月) | 2,448,110 |
| 市值 | 6,793,679 |
| 股市价格/股市净资产 (P/B) | 1.26 |
| 52周波幅 |
| 营业利益率 (TTM) | -148,318.41% |
| 稀释每股收益 (EPS TTM) | 1.72 |
| 季度收入增长率 (YOY) | -100.00% |
| 总债务/股东权益 (D/E MRQ) | 10.75% |
| 流动比率 (MRQ) | 3.02 |
| 营业现金流 (OCF TTM) | -10.24 M |
| 杠杆自由现金流 (LFCF TTM) | -6.32 M |
| 资产报酬率 (ROA TTM) | -116.11% |
| 股东权益报酬率 (ROE TTM) | -208.50% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Azitra Inc | - | - |
AIStockmoo 评分
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -2.5 |
| 相对估值 | NA |
| 财务健康 | NA |
| 宏观环境 | 0.0 |
| AI Insight | NA |
| 平均 | -0.40 |
|
Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 7.95% |
| 机构持股比例 | 4.52% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Dauntless Investment Group, Llc | 30 Jun 2026 | 1,129,219 |
| Stonepine Capital Management, Llc | 30 Jun 2026 | 528,548 |
| Nantahala Capital Management, Llc | 30 Jun 2026 | 221,361 |
| Tower Research Capital Llc (Trc) | 30 Jun 2026 | 1,950 |
| Corient Private Wealth Lp | 30 Jun 2026 | 1,445 |
该时间范围内无数据。
该时间范围内无数据。
投资组合